News
![Augtyro](/sites/default/files/styles/x_large/public/2024-06/Augtyro-pac-BMS.jpg?itok=1KZlWyPL)
FDA widens label for BMS’ cancer drug Augtyro
Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti